Όλο το DSpace

Πλοήγηση ανά Θέμα "dabigatran"

Αποτελέσματα 1-20 από 27

    • Adherence to oral anticoagulation in ischemic stroke patients with atrial fibrillation 

      Tiili P., Leventis I., Kinnunen J., Svedjebäck I., Lehto M., Karagkiozi E., Sagris D., Ntaios G., Putaala J. (2021)
      Background: Non-vitamin K antagonist oral anticoagulants (NOAC) have superior safety and comparable efficacy profile compared to vitamin-K antagonists (VKAs), with more convenient dosing schemes. However, issues with ...

    • Assessment of the reporting quality of RCTs for novel oral anticoagulants in venous thromboembolic disease based on the CONSORT statement 

      Liampas I., Chlinos A., Siokas V., Brotis A., Dardiotis E. (2019)
      Randomized controlled trials (RCTs) are the cornerstone of evidence based medicine. Ιt is crucial that RCTs have transparent reporting to facilitate their interpretation. The purpose of the present study is the evaluation ...

    • Bleeding risk comparison between direct oral anticoagulants at doses approved for atrial fibrillation and aspirin: systematic review, meta-analysis and meta-regression 

      Sagris D., Leventis I., Georgiopoulos G., Korompoki E., Makaritsis K., Vemmos K., Milionis H., Lip G.Y.H., Ntaios G. (2020)
      Background: A considerable proportion of patients with atrial fibrillation (AF) are still treated with aspirin despite current guidelines due to presumed favorable safety. Aim: We performed a systematic review and meta-analysis ...

    • Causes and Risk Factors of Cerebral Ischemic Events in Patients with Atrial Fibrillation Treated with Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention: The RENo Study 

      Paciaroni M., Agnelli G., Caso V., Silvestrelli G., Seiffge D.J., Engelter S., De Marchis G.M., Polymeris A., Zedde M.L., Yaghi S., Michel P., Eskandari A., Antonenko K., Sohn S.-I., Cappellari M., Tassinari T., Tassi R., Masotti L., Katsanos A.H., Giannopoulos S., Acciarresi M., Alberti A., Venti M., Mosconi M.G., Vedovati M.C., Pierini P., Giustozzi M., Lotti E.M., Ntaios G., Kargiotis O., Monaco S., Lochner P., Bandini F., Liantinioti C., Palaiodimou L., Abdul-Rahim A.H., Lees K., Mancuso M., Pantoni L., Rosa S., Bertora P., Galliazzo S., Ageno W., Toso E., Angelini F., Chiti A., Orlandi G., Denti L., Flomin Y., Marcheselli S., Mumoli N., Rimoldi A., Verrengia E., Schirinzi E., Del Sette M., Papamichalis P., Komnos A., Popovic N., Zarkov M., Rocco A., Diomedi M., Giorli E., Ciccone A., Grory B.C.M., Furie K.L., Bonetti B., Saia V., Guideri F., Acampa M., Martini G., Grifoni E., Padroni M., Karagkiozi E., Perlepe K., Makaritsis K., Mannino M., MacCarrone M., Ulivi L., Giannini N., Ferrari E., Pezzini A., Doronin B., Volodina V., Baldi A., D'Amore C., Deleu D., Corea F., Putaala J., Santalucia P., Nardi K., Risitano A., Toni D., Tsivgoulis G. (2019)
      Background and Purpose-Despite treatment with oral anticoagulants, patients with nonvalvular atrial fibrillation (AF) may experience ischemic cerebrovascular events. The aims of this case-control study in patients with AF ...

    • Consensus statements and recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 11–13 November 2018 

      Ahmed N., Audebert H., Turc G., Cordonnier C., Christensen H., Sacco S., Sandset E.C., Ntaios G., Charidimou A., Toni D., Pristipino C., Köhrmann M., Kuramatsu J.B., Thomalla G., Mikulik R., Ford G.A., Martí-Fàbregas J., Fischer U., Thoren M., Lundström E., Rinkel G.J.E., Worp H.B.V.D., Matusevicius M., Tsivgoulis G., Milionis H., Rubiera M., Hart R., Moreira T., Lantz M., Sjöstrand C., Andersen G., Schellinger P., Kostulas K., Sunnerhagen K.S., Keselman B., Korompoki E., Purrucker J., Khatri P., Whiteley W., Berge E., Mazya M., Dippel D.W.J., Mustanoja S., Rasmussen M., Söderqvist Å.K., Escudero-Martínez I., Steiner T. (2019)
      The purpose of the European Stroke Organisation–Karolinska Stroke Update Conference is to provide updates on recent stroke therapy research and to give an opportunity for the participants to discuss how these results may ...

    • Dabigatran Reversal With Idarucizumab and In-Hospital Mortality in Intracranial Hemorrhage: A Systematic Review of Real-Life Data From Case Reports and Case Series 

      Frol S., Sagris D., Šabovič M., Ntaios G., Oblak J.P. (2021)
      Background: Intracranial hemorrhage is a severe and possibly fatal consequence of anticoagulation therapy. Idarucizumab is used in dabigatran-treated patients suffering from intracranial hemorrhage (ICH) to reverse the ...

    • Difficult situations in anticoagulation after stroke: Between Scylla and Charybdis 

      Ntaios G., Lip G.Y.H. (2016)
      Purpose of review A significant proportion of stroke patients is treated with anticoagulants for secondary stroke prevention. Often, in such patients, stroke physicians are required to make difficult clinical decisions ...

    • Direct oral anticoagulant-vs Vitamin K antagonist-related nontraumatic intracerebral hemorrhage 

      Tsivgoulis G., Lioutas V.-A., Varelas P., Katsanos A.H., Goyal N., Mikulik R., Barlinn K., Krogias C., Sharma V.K., Vadikolias K., Dardiotis E., Karapanayiotides T., Pappa A., Zompola C., Triantafyllou S., Kargiotis O., Ioakeimidis M., Giannopoulos S., Kerro A., Tsantes A., Mehta C., Jones M., Schroeder C., Norton C., Bonakis A., Chang J., Alexandrov A.W., Mitsias P., Alexandrov A.V. (2017)
      Objective: To compare the neuroimaging profile and clinical outcomes among patients with intracerebral hemorrhage (ICH) related to use of vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) for nonvalvular ...

    • Early recurrence and major bleeding in patients with acute ischemic stroke and atrial fibrillation treated with Non-Vitamin-K oral anticoagulants (RAF-NOACs) Study 

      Paciaroni M., Agnelli G., Falocci N., Tsivgoulis G., Vadikolias K., Liantinioti C., Chondrogianni M., Bovi P., Carletti M., Cappellari M., Zedde M., Ntaios G., Karagkiozi E., Athanasakis G., Makaritsis K., Silvestrelli G., Lanari A., Ciccone A., Putaala J., Tomppo L., Tatlisumak T., Abdul-Rahim A.H., Lees K.R., Alberti A., Venti M., Acciarresi M., D'Amore C., Becattini C., Mosconi M.G., Cimini L.A., Soloperto R., Masotti L., Vannucchi V., Lorenzini G., Tassi R., Guideri F., Acampa M., Martini G., Sohn S.-I., Marcheselli S., Mumoli N., De Lodovici M.L., Bono G., Furie K.L., Tadi P., Yaghi S., Toni D., Letteri F., Tassinari T., Kargiotis O., Lotti E.M., Flomin Y., Mancuso M., Maccarrone M., Giannini N., Bandini F., Pezzini A., Poli L., Padovani A., Scoditti U., Denti L., Consoli D., Galati F., Sacco S., Carolei A., Tiseo C., Gourbali V., Orlandi G., Giuntini M., Chiti A., Giorli E., Gialdini G., Corea F., Ageno W., Bellesini M., Colombo G., Monaco S., Baronello M.M., Karapanayiotides T., Caso V. (2017)
      Background--The optimal timing to administer non-vitamin K oral anticoagulants (NOACs) in patients with acute ischemic stroke and atrial fibrillation is unclear. This prospective observational multicenter study evaluated ...

    • Early recurrence in paroxysmal versus sustained atrial fibrillation in patients with acute ischaemic stroke 

      Paciaroni M., Angelini F., Agnelli G., Tsivgoulis G., Furie K.L., Tadi P., Becattini C., Falocci N., Zedde M., Abdul-Rahim A.H., Lees K.R., Alberti A., Venti M., Acciarresi M., Altavilla R., D’Amore C., Mosconi M.G., Cimini L.A., Bovi P., Carletti M., Rigatelli A., Cappellari M., Putaala J., Tomppo L., Tatlisumak T., Bandini F., Marcheselli S., Pezzini A., Poli L., Padovani A., Masotti L., Vannucchi V., Sohn S.-I., Lorenzini G., Tassi R., Guideri F., Acampa M., Martini G., Ntaios G., Karagkiozi E., Athanasakis G., Makaritsis K., Vadikolias K., Liantinioti C., Chondrogianni M., Mumoli N., Consoli D., Galati F., Sacco S., Carolei A., Tiseo C., Corea F., Ageno W., Bellesini M., Silvestrelli G., Ciccone A., Scoditti U., Denti L., Mancuso M., Maccarrone M., Orlandi G., Giannini N., Gialdini G., Tassinari T., Lodovici M.L.D., Bono G., Rueckert C., Baldi A., Toni D., Letteri F., Giuntini M., Lotti E.M., Flomin Y., Pieroni A., Kargiotis O., Karapanayiotides T., Monaco S., Baronello M.M., Csiba L., Szabó L., Chiti A., Giorli E., Sette M.D., Imberti D., Zabzuni D., Doronin B., Volodina V., Michel Pd-Mer P., Vanacker P., Barlinn K., Pallesen L.P., Kepplinger J., Deleu D., Melikyan G., Ibrahim F., Akhtar N., Gourbali V., Yaghi S., Caso V. (2019)
      Background: The relationship between different patterns of atrial fibrillation and early recurrence after an acute ischaemic stroke is unclear. Purpose: In a prospective cohort study, we evaluated the rates of early ischaemic ...

    • Effectiveness and safety of intracranial events associated with the use of direct oral anticoagulants for atrial fibrillation: A systematic review and meta-analysis of 92 studies 

      Archontakis-Barakakis P., Li W., Kalaitzoglou D., Tzelves L., Manolopoulos A., Giannopoulos S., Giamouzis G., Giannakoulas G., Batsidis A., Palaiodimos L., Ntaios G., Lip G.Y.H., Kokkinidis D.G. (2022)
      Aims: Observational studies have investigated the effectiveness and safety of direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) used in nonvalvular atrial fibrillation. We performed a systematic review ...

    • Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias 

      Bawazeer G.A., Alkofide H.A., Alsharafi A.A., Babakr N.O., Altorkistani A.M., Kashour T.S., Miligkos M., AlFaleh K.M., Al-Ansary L.A. (2021)
      Background: The management of anticoagulation therapy around the time of catheter ablation (CA) procedure for adults with arrhythmia is critical and yet is variable in clinical practice. The ideal approach for safe and ...

    • Intravenous Thrombolysis After Dabigatran Reversal by Idarucizumab: A Systematic Review of the Literature 

      Frol S., Sagris D., Pretnar Oblak J., Šabovič M., Ntaios G. (2021)
      Background and Purpose: Idarucizumab achieves instant reversal of anticoagulation and enables intravenous thrombolysis (IVT) in dabigatran-treated acute ischemic stroke (AIS) patients. AIS in dabigatran-treated patients ...

    • Major Hemorrhage Risk Associated with Direct Oral Anticoagulants in Non-Valvular Atrial Fibrillation: A Systematic Review and Meta-Analysis 

      Archontakis-Barakakis P., Kokkinidis D.G., Nagraj S., Gidwani V., Mavridis T., Ntaios G. (2022)
      Background: Real-world, observational studies have investigated the safety profile of Direct Oral Anticoagulants (DOACs) on Major Hemorrhage (MH) used for stroke prevention in Non-Valvular Atrial Fibrillation (NVAF). We ...

    • Neuroimaging and clinical outcomes of oral anticoagulant–associated intracerebral hemorrhage 

      Tsivgoulis G., Wilson D., Katsanos A.H., Sargento-Freitas J., Marques-Matos C., Azevedo E., Adachi T., von der Brelie C., Aizawa Y., Abe H., Tomita H., Okumura K., Hagii J., Seiffge D.J., Lioutas V.-A., Traenka C., Varelas P., Basir G., Krogias C., Purrucker J.C., Sharma V.K., Rizos T., Mikulik R., Sobowale O.A., Barlinn K., Sallinen H., Goyal N., Yeh S.-J., Karapanayiotides T., Wu T.Y., Vadikolias K., Ferrigno M., Hadjigeorgiou G., Houben R., Giannopoulos S., Schreuder F.H.B.M., Chang J.J., Perry L.A., Mehdorn M., Marto J.-P., Pinho J., Tanaka J., Boulanger M., Salman R.A.-S., Jäger H.R., Shakeshaft C., Yakushiji Y., Choi P.M.C., Staals J., Cordonnier C., Jeng J.-S., Veltkamp R., Dowlatshahi D., Engelter S.T., Parry-Jones A.R., Meretoja A., Mitsias P.D., Alexandrov A.V., Ambler G., Werring D.J. (2018)
      Objective: Whether intracerebral hemorrhage (ICH) associated with non–vitamin K antagonist oral anticoagulants (NOAC-ICH) has a better outcome compared to ICH associated with vitamin K antagonists (VKA-ICH) is uncertain. ...

    • Non-vitamin-K oral anticoagulants (NOACs) for the prevention of secondary stroke 

      Diener H.-C., Ntaios G., O’Donnell M., Easton J.D. (2018)
      Introduction: In patients with atrial fibrillation (AF), oral anticoagulation with vitamin K antagonists (VKA) (warfarin, phenprocoumon) is effective both for primary and secondary stroke prevention with a 60–70% relative ...

    • Nonvitamin-K-Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack A Systematic Review and Meta-Analysis of Randomized Controlled Trials 

      Ntaios, G.; Papavasileiou, V.; Diener, H. C.; Makaritsis, K.; Michel, P. (2012)
      Background and Purpose-To assess whether the combined analysis of all phase III trials of nonvitamin-K-antagonist (non-VKA) oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic ...

    • Oral anticoagulation versus antiplatelet or placebo for stroke prevention in patients with heart failure and sinus rhythm: Systematic review and meta-analysis of randomized controlled trials 

      Ntaios G., Vemmos K., Lip G.Y.H. (2019)
      Background: Previous meta-analyses of randomized controlled trials of oral anticoagulation in patients with heart failure and sinus rhythm reported reduced stroke risk and increased bleeding risk compared to antiplatelets ...

    • Perioperative management of DOACs in vascular surgery: A practical approach 

      Kouvelos G., Matsagkas M., Rousas N., Nana P., Mpatzalexis K., Stamoulis K., Giannoukas A., Arnaoutoglou E. (2018)
      Background: Approximately 10–15% of patients on DOACs have to interrupt their anticoagulant before an invasive procedure every year. The perioperative management and monitoring of DOACs have proved to be challenging, as ...

    • Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry 

      Giannis D., Allen S.L., Tsang J., Flint S., Pinhasov T., Williams S., Tan G., Thakur R., Leung C., Snyder M., Bhatia C., Garrett D., Cotte C., Isaacs S., Gugerty E., Davidson A., Marder G.S., Schnitzer A., Goldberg B., McGinn T., Davidson K.W., Barish M.A., Qiu M., Zhang M., Goldin M., Matsagkas M., Arnaoutoglou E., Spyropoulos A.C. (2021)
      Thromboembolic events, including venous thromboembolism (VTE) and arterial thromboembolism (ATE), and mortality from subclinical thrombotic events occur frequently in coronavirus disease 2019 (COVID-19) inpatients. Whether ...